Reid, Reiss, Redman, James Edward ![]() ![]() ![]() ![]() |
Preview |
PDF
- Accepted Post-Print Version
Download (818kB) | Preview |
Preview |
PDF
Download (751kB) | Preview |
Abstract
We set out to clone Bax-specific CD8+ T cells from peripheral blood sam- ples of patients with primary chronic lymphocytic leukaemia. A number of clones were generated using a Bax peptide pool and their T-cell epitope was mapped to two peptides sharing a common 9-amino-acid sequence (LLSYFGTPT), restricted by HLA-A*0201. However, when these T-cell clones were tested against highly purified syntheses (> 95%) of the same peptide sequence, there was no functional response. Subsequent mass spectrometric analysis and HPLC fractionation suggested that the active component in the original crude peptide preparations (77% pure) was a peptide with a tert-butyl (tBu) modification of the tyrosine residue. This was confirmed by modification of the inactive wild-type sequence to gen- erate functionally active peptides. Computer modelling of peptide:HLA- A*0201 structures predicted that the tBu modification would not affect interactions between peptide residues and the HLA binding site. However, these models did predict that the tBu modification of tyrosine would result in an extension of the side chain out of the peptide-binding groove up towards the T-cell receptor. This modified product formed < 1% of the original P603 crude peptide preparation and < 0.05% of the origi- nal 23-peptide mixture used for T-cell stimulation. The data presented here, illustrate the potential for chemical modifications to change the immunogenicity of synthetic peptides, and highlight the exquisite capacity of T-cell receptors to discriminate between structurally similar peptide sequences. Furthermore, this study highlights potential pitfalls associated with the use of synthetic peptides for the monitoring and modulating of human immune responses.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Chemistry Medicine |
Subjects: | Q Science > QD Chemistry Q Science > QR Microbiology > QR180 Immunology |
Publisher: | Wiley Blackwell |
ISSN: | 0019-2805 |
Funders: | MRC, Leukaemia Lymphoma Research, Cancer Research Wales, Cardiff University |
Date of First Compliant Deposit: | 30 March 2016 |
Date of Acceptance: | 30 September 2014 |
Last Modified: | 29 Mar 2024 10:00 |
URI: | https://orca.cardiff.ac.uk/id/eprint/67727 |
Citation Data
Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |